China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years

In the United States, Biogen announced that, after consulting with the U.S. Food and Drug Administration (FDA), the company plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease.
China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years
 https://www.scmp.com/news/china/science/article/